SynthesisNeuroradiology2016
Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics.
Synthesis in Neuroradiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis.AJNR. American journal of neuroradiology · 2017Pooled it
- Imaging diagnosis of cystic intraparenchymal brain neoplasms.Japanese journal of radiology · 2026Review
- Lipid metabolism as a marker for glioma aggressiveness.Bioscience reports · 2026Article
- Diagnostic Accuracy ofJournal of magnetic resonance imaging : JMRI · 2025Article
- Metabolic signatures derived from whole-brain MR-spectroscopy identify early tumor progression in high-grade gliomas using machine learning.Journal of neuro-oncology · 2024Article
- 7 Tesla magnetic resonance spectroscopic imaging predicting IDH status and glioma grading.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Peak Resembling N-acetylaspartate (NAA) on Magnetic Resonance Spectroscopy of Brain Metastases.Medicina (Kaunas, Lithuania) · 2024Article
- The multidisciplinary management of HER2-positive breast cancer brain metastases: from new biological insights to future therapeutic options.Frontiers in oncology · 2024Review
- Magnetic resonance-based imaging biopsy with signatures including topological Betti number features for prediction of primary brain metastatic sites.Physical and engineering sciences in medicine · 2023Article
- Revisiting the use of proton magnetic resonance spectroscopy in distinguishing between primary and secondary malignant tumors of the central nervous system.The neuroradiology journal · 2022Article
- Multiparametric Characterization of Intracranial Gliomas Using Dynamic [18F]FET-PET and Magnetic Resonance Spectroscopy.Diagnostics (Basel, Switzerland) · 2022Article
- [MRI reporting of gliomas : What neuro-oncology clinicians expect from radiologists].Radiologie (Heidelberg, Germany) · 2022Article
- CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.European journal of nuclear medicine and molecular imaging · 2022Article
- The Use ofDiagnostics (Basel, Switzerland) · 2022Review
- Advanced magnetic resonance imaging findings of cerebellar hemangioblastomas: A report of three cases and a literature review.Acta radiologica open · 2022Article
- Case report: immunotherapy successfully treated brain metastasis in intrahepatic cholangiocarcinoma and literature review.Frontiers in oncology · 2022Article
- Comparison of the diagnostic value of liquid biopsy in leptomeningeal metastases: A systematic review and meta-analysis.Frontiers in oncology · 2022Review
- Inorganic Nanomaterial for Biomedical Imaging of Brain Diseases.Molecules (Basel, Switzerland) · 2021Review
- Radiomics and radiogenomics in gliomas: a contemporary update.British journal of cancer · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo perform a meta-analysis of advanced magnetic resonance imaging (MRI) metrics, including relative cerebral blood volume (rCBV), normalized apparent diffusion coefficient (nADC), and spectroscopy ratios choline/creatine (Cho/Cr) and choline/N-acetyl aspartate (Cho/NAA), for the differentiation of high- and low-grade gliomas (HGG, LGG) and metastases (MTS).
methodsFor systematic review, 83 articles (dated 2000-2013) were selected from the NCBI database. Twenty-four, twenty-two, and eight articles were included respectively for spectroscopy, rCBV, and nADC meta-analysis. In the meta-analysis, we calculated overall means for rCBV, nADC, Cho/Cr (short TE-from 20 to 35 ms, medium-from 135 to 144 ms), and Cho/NAA for the HGG, LGG, and MTS groups. We used random effects model to obtain weighted averages and select thresholds.
resultsOverall means (with 95% CI) for rCBV, nADC, Cho/Cr (short and medium echo time, TE), and Cho/NAA were: for HGG 5.47 (4.78-6.15), 1.38 (1.16-1.60), 2.40 (1.67-3.13), 3.27 (2.78-3.77), and 4.71 (3.24-6.19); for LGG 2.00 (1.71-2.28), 1.61 (1.36-1.87), 1.46 (1.20-1.72), 1.71 (1.49-1.93), and 2.36 (1.50-3.23); for MTS 5.06 (3.85-6.27), 1.35 (1.06-1.64), 1.89 (1.72-2.06), 3.14 (1.57-4.72), (Cho/NAA was not available). LGG had significantly lower rCBV, Cho/Cr, and Cho/NAA values than HGG or MTS. No significant differences were found for nADC.
conclusionsBest differentiation between HGG and LGG is obtained from rCBV, Cho/Cr, and Cho/NAA metrics. MTS could not be reliably distinguished from HGG by the methods investigated.
Indexed as
Identifiers
26767528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.